EMA to review Marketing Authorisation of GW Pharma’s cannibidiol
EMA has accepted GW Pharmaceuticals’ request to review the MMA (Marketing Authorisation Application) of Epidiolex, or cannibidiol. The treatment is currently used on patients who suffer from seizures linked to Lennox-Gastaut syndrome and Dravet syndrome. GW Pharmaceuticals first submitted Epidiolex for review in December 2017. The successful filing of the MAA of the drug follows